Overview
WW fiscal Q2 rev declines 6% yr/yr, Clinical rev grows 55%
Co completes strategic reorganization, reduces debt by $1.15 bln
Predecessor net income margin impacted by reorganization items in fiscal Q2
Outlook
Company projects full-year revenue of $685 mln to $700 mln
WW International expects adjusted EBITDA of $140 mln to $150 mln
Company cites ongoing challenges in behavioral business impacting revenue
Result Drivers
DEBT REDUCTION - Co completed strategic reorganization, reducing debt by $1.15 bln
CLINICAL GROWTH - Clinical revenues rose 55% yr/yr, driven by compounded semaglutide subscriptions
BEHAVIORAL CHALLENGES - Revenue decline attributed to ongoing headwinds in behavioral business
Key Details
Press Release: ID:nGNX3mWcLB
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)